Published in Eur J Clin Microbiol Infect Dis on April 01, 1991
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1993) 4.27
Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1995) 2.52
Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res (2001) 2.40
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother (2005) 1.35
Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol (1996) 1.29
Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.21
Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother (1999) 1.21
Quinolone mode of action--new aspects. Drugs (1993) 0.99
In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites. Nucleic Acids Res (1997) 0.98
Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli. BMC Microbiol (2013) 0.98
Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis. Antimicrob Agents Chemother (1996) 0.94
Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids. Antimicrob Agents Chemother (2003) 0.86
The future of the quinolones. Drugs (1993) 0.84
Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection (1994) 0.81
Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis. Antimicrob Agents Chemother (1998) 0.78
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother (1989) 5.09
Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore) (1984) 5.04
Fluoroquinolone antimicrobial agents. N Engl J Med (1991) 4.65
Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother (1988) 4.47
Mechanisms of action of and resistance to ciprofloxacin. Am J Med (1987) 4.46
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Cryptosporidiosis in immunocompetent patients. N Engl J Med (1985) 3.62
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother (1982) 3.15
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother (1989) 2.99
Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol (1988) 2.71
Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med (1985) 2.07
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother (1993) 2.04
Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med (1991) 1.88
Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother (1992) 1.54
An association between cryptosporidium and giardia in stool. N Engl J Med (1984) 1.43
Antagonism of the B subunit of DNA gyrase eliminates plasmids pBR322 and pMG110 from Escherichia coli. J Bacteriol (1982) 1.29
Infection in the renal transplant recipient. Am J Med (1981) 1.25
Bacterial resistance to the quinolone antimicrobial agents. Am J Med (1989) 1.23
Mode of action of the quinolone antimicrobial agents. Rev Infect Dis (1988) 1.16
Rapid method for screening large numbers of Escherichia coli colonies for production of plasmid-mediated beta-lactamases. Antimicrob Agents Chemother (1983) 1.15
Novobiocin-induced elimination of F'lac and mini-F plasmids from Escherichia coli. J Bacteriol (1983) 1.07
Mode of action of the quinolone antimicrobial agents: review of recent information. Rev Infect Dis (1989) 1.01
Elimination of plasmid pMG110 from Escherichia coli by novobiocin and other inhibitors of DNA gyrase. Antimicrob Agents Chemother (1984) 1.00
Dermatologic manifestations of infection in the compromised host. Annu Rev Med (1983) 0.97
Knotting of DNA molecules isolated from deletion mutants of intact bacteriophage P4. Nucleic Acids Res (1985) 0.95
Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother (1989) 0.92
Toxic-shock syndrome. N Engl J Med (1980) 0.92
Dirofilaria ursi-like parasites acquired by humans in the northern United States and Canada: report of two cases and brief review. Am J Trop Med Hyg (1987) 0.92
Adrenal crisis in the setting of high-dose ketoconazole therapy. Arch Intern Med (1989) 0.85
Novobiocin antagonism of amastigotes of Trypanosoma cruzi growing in cell-free medium. Antimicrob Agents Chemother (1986) 0.84
Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore) (1985) 0.84
Effects of inhibition of the B subunit of DNA gyrase on conjugation in Escherichia coli. J Bacteriol (1989) 0.82
Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium. J Protozool (1989) 0.79
Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med (1977) 0.79
Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates. Eur J Clin Microbiol Infect Dis (1992) 0.78
Visualization of the mitochondrion-kinetoplast in viable Trypanosoma cruzi with rhodamine 123. J Parasitol (1987) 0.75
Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles. Curr Clin Top Infect Dis (1989) 0.75